Overactive Bladder
Conditions
Keywords
Urology, TENS, Overactive bladder
Brief summary
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management. While effectiveness of TC-pTNS has been demonstrated in the literature, the success rate is heterogeneous, depending on the clinical picture. In an effort to ascertain clearly the efficacy of Tensi+ device, as well as its safety of use and assess comfort of use, the present study will evaluate the results of Tensi+ treatment in real life conditions in a prospective study. The main objective is to assess the efficacy (actual clinical benefit) of TC-pTNS with Tensi+ device for management of overactive bladder in an adult population at 3 months. Included patients are prescribed a treatment with Tensi+ for 3 months. An evaluation visit is scheduled at 3 months. In treatment is continued, a follow-up visit is scheduled at 6 months. Primary outcome measure Success at 3 months defined as a composite parameter: (i) Objective improvement, with at least 30% decrease of urgency episodes compared to baseline on 3-day bladder diary AND (ii) Subjective improvement, with patient Global Impression of Improvement score of 1 or 2 Time point(s) at which primary outcome measure is assessed : 3 months Secondary outcome measures (i) Evaluation of urinary symptoms based on bladder diary parameters (urinary frequency, incontinence episodes, maximum bladder capacity, nocturia episodes) and the Urinary Symptom Profile (USP) questionnaire (ii) Evaluation of adverse events (iii) Patient-reported Outcomes Measures (PROMs): Comfort of use (VAS in deciles), recommendation to another patient (binary), consumer grading regarding device usability details (iv) Quality of life measures (OABq questionnaire, VAS scale) (vii) Assessment of treatment persistence Time point(s) at which Secondary outcome measure is assessed\* : at 3 months and 6 months Inclusion criteria : Age ≥ 18 years Overactive bladder symptoms Number of subjects : 100
Interventions
DEVICETensi+
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
Sponsors
Stimuli Technology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Patients suffering from Overactive bladder symptoms
Exclusion criteria
* Pregnancy * Patients with active implantable device or ankle orthopedic implant, * Ankle articular diseases. * Prior treatment with transcutaneous PTNS or percutaneous PTNS (any time), * Sacral neuromodulation (anytime) or, * Intradetrusor botulinum toxin injection within the past 6 months * Antimuscarinic use within 1 month prior to the study * 24hour diuresis \> 2800cc on bladder diary * Known bladder disease * Active urinary tract infection * PVR\> 150 ml * Pelvic organ prolapse stage \>2 * Predominant stress urinary incontinence * Cognitive impairment * Inability to use the device without a third party * Inability to complete a bladder diary * No health insurance coverage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective improvement | At 3 months | At least 30% decrease of urgency episodes compared to baseline on 3-day bladder diary |
| Subjective improvement | At 3 months | Patient Global Impression of Improvement score of 1 or 2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient-reported Outcomes Measures (PROMs) | At 3 months and 6 months | Comfort of use, recommendation to another patient (binary), consumer grading regarding device usability details |
| Evaluation of urinary symptoms | At 3 months and 6 months | Bladder diary parameters evaluation (urinary frequency, incontinence episodes, maximum bladder capacity, nocturia episodes) and the Urinary Symptom Profile (USP) questionnaire |
| Assessment of treatment persistence | At 3 months and 6 months | — |
| Quality of life measures | At 3 months and 6 months | By filling up OABq questionnaire and VAS scale |
| Evaluation of adverse events | At 3 months and 6 months | Questions to be asked to patients at 3 months and 6 months if there were any adverse events during treatment |
Countries
France
Outcome results
None listed